<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244880</url>
  </required_header>
  <id_info>
    <org_study_id>A8241014</org_study_id>
    <nct_id>NCT01244880</nct_id>
  </id_info>
  <brief_title>Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects</brief_title>
  <official_title>Subject And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 2-Way, 4-Period Crossover Study To Assess Effects Of PF-02545920 On Ketamine-Induced Aberrant Prefrontal Response To Associative Learning In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether PF-02545920 reduces the effects of ketamine on brain activation during
      causal learning as measured by fMRI compared to placebo in healthy human subjects, and to
      evaluate whether behavioral measures of abnormal causal learning under ketamine are reduced
      by treatment with PF 02545920.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was terminated on November 2, 2012 due to a reassessment of the likelihood of the
      study meeting its scientific objectives in light of data with the investigational drug
      obtained from another clinical study. The decision to terminate the trial was not based on
      any safety concerns.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lateral prefrontal cortex activation as measured by functional MRI (fMRI) BOLD imaging during causal learning and working memory tasks</measure>
    <time_frame>Day 1 of each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lateral prefrontal cortex activation during causal learning and working memory tasks as measured by arterial spin labelling imaging</measure>
    <time_frame>Day 1 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Causal learning task prediction error score for stimulus/outcome associations across 3 stages of learning and expectancy violation</measure>
    <time_frame>Day 1 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-back working memory task number correct</measure>
    <time_frame>Day 1 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS) positive and negative subscale total score</measure>
    <time_frame>Day 1 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician administered dissociative states scale (CADSS) total score</measure>
    <time_frame>Day 1 of each treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Saline/PF-02545920</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatments are co-administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine/PF-02545920</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatments are co-administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline/Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatments are co-administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatments are co-administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline infusion for 56 minutes</description>
    <arm_group_label>Saline/PF-02545920</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02545920</intervention_name>
    <description>PF-02545920 10 mg single dose</description>
    <arm_group_label>Saline/PF-02545920</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes
PF-02545920 10 mg tablet</description>
    <arm_group_label>Ketamine/PF-02545920</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02545920</intervention_name>
    <description>PF-02545920 10 mg tablet single dose</description>
    <arm_group_label>Ketamine/PF-02545920</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline infusion for 56 minutes</description>
    <arm_group_label>Saline/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet single dose</description>
    <arm_group_label>Saline/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes</description>
    <arm_group_label>Ketamine/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet single dose</description>
    <arm_group_label>Ketamine/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 21 and 45 years, inclusive.
             Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).
             (Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12 lead ECG and clinical laboratory tests).

          -  Right handed as determined by handedness questionnaire.

          -  Able to read and write English as a primary language.

        Exclusion Criteria:

          -  Female subjects who are pregnant or breastfeeding.

          -  Any evidence of significant psychosis-like symptoms.

          -  Known sensitivity to ketamine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8241014&amp;StudyName=Effects%20Of%20PF-02545920%20On%20Ketamine-Induced%20Abnormal%20Prefrontal%20Brain%20Response%20To%20Associative%20Learning%20In%20Healthy%20Subjects%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-02545920</keyword>
  <keyword>ketamine</keyword>
  <keyword>fMRI</keyword>
  <keyword>associative Learning</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

